These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

53 related items for PubMed ID: 19916705

  • 21. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study.
    Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI.
    Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881
    [Abstract] [Full Text] [Related]

  • 22. Starting or switching to biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes: a multicenter, observational, primary care study conducted in Finland.
    Mäkelä JK, Schmüser C, Askonen K, Saukkonen T.
    Diabetes Res Clin Pract; 2012 Jan; 95(1):10-8. PubMed ID: 22078072
    [Abstract] [Full Text] [Related]

  • 23. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study.
    Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Wenying Y.
    Diabetes Res Clin Pract; 2011 Dec; 94(3):352-63. PubMed ID: 22153567
    [Abstract] [Full Text] [Related]

  • 24. The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study.
    Esteghamati A, Rajabian R, Amini M, Bahrami A, Khamseh ME, Afkhami-Ardekani M, Rizi EP.
    Endokrynol Pol; 2010 Dec; 61(4):364-70. PubMed ID: 20806180
    [Abstract] [Full Text] [Related]

  • 25. The IMPROVE study--a multinational, observational study in type 2 diabetes: data from the Polish cohort.
    Gumprecht J, Zurawska G, Wolnik B, Dzida G.
    Endokrynol Pol; 2008 Dec; 59(6):460-6. PubMed ID: 19347809
    [Abstract] [Full Text] [Related]

  • 26. Effect of biphasic insulin aspart on glucose and lipid control in patients with Type 2 diabetes mellitus.
    Lalić NM, Micić D, Antić S, Bajović L, Pantelinac P, Jotić A, Kendereski A, Dimić D, Djukić A, Mitrović M, Vujasin M.
    Expert Opin Pharmacother; 2007 Dec; 8(17):2895-901. PubMed ID: 18001251
    [Abstract] [Full Text] [Related]

  • 27. Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan.
    Ishii H, Iwase M, Seino H, Shuto Y, Atsumi Y.
    Curr Med Res Opin; 2011 Mar; 27(3):643-50. PubMed ID: 21250861
    [Abstract] [Full Text] [Related]

  • 28. Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life.
    Pollack MF, Purayidathil FW, Bolge SC, Williams SA.
    Diabetes Res Clin Pract; 2010 Feb; 87(2):204-10. PubMed ID: 20036433
    [Abstract] [Full Text] [Related]

  • 29. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study.
    Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L.
    Diabetes Res Clin Pract; 2011 Dec; 94(3):364-70. PubMed ID: 22153568
    [Abstract] [Full Text] [Related]

  • 30. Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results.
    Güler S, Sharma SK, Almustafa M, Kim CH, Azar S, Danciulescu R, Shestakova M, Khutsoane D, Bech OM.
    Arch Drug Inf; 2009 Jun; 2(2):23-33. PubMed ID: 19684847
    [Abstract] [Full Text] [Related]

  • 31. Management of Chinese patients with type 2 diabetes, 1998-2006: the Diabcare-China surveys.
    Pan C, Yang W, Jia W, Weng J, Tian H.
    Curr Med Res Opin; 2009 Jan; 25(1):39-45. PubMed ID: 19210137
    [Abstract] [Full Text] [Related]

  • 32. Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the 'Darwin study'.
    Packianathan IC, Fuller NJ, Peterson DB, Wright A, Coward WA, Finer N.
    Diabetologia; 2005 Feb; 48(2):222-9. PubMed ID: 15688205
    [Abstract] [Full Text] [Related]

  • 33. Effect of dietary calcium intake on weight gain in type 2 diabetic patients following initiation of insulin therapy.
    Duengler F, Torremocha F, Yameogo M, Marechaud R, Hadjadj S.
    Diabetes Metab; 2006 Sep; 32(4):358-63. PubMed ID: 16977264
    [Abstract] [Full Text] [Related]

  • 34. Association Between Pharmacological Treatment Regimens and Quality of Life Among Rural Type 2 Diabetic Patients: A Comparative Analysis in Eastern China.
    Li S, Zhao S, Wang L, Wu X, Zhang Z, Wang Z.
    Inquiry; 2024 Sep; 61():469580241288683. PubMed ID: 39415363
    [Abstract] [Full Text] [Related]

  • 35. Course of body weight before and after the initiation of insulin therapy in type 2 diabetes mellitus: Retrospective inception cohort study (ZODIAC 58).
    Edens MA, van Dijk PR, Hak E, Bilo HJG.
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00212. PubMed ID: 33855214
    [Abstract] [Full Text] [Related]

  • 36. Insulin therapy does not itself induce weight gain in patients with type 2 diabetes.
    Larger E, Rufat P, Dubois-Laforgue D, Ledoux S.
    Diabetes Care; 2001 Oct; 24(10):1849-50. PubMed ID: 11574460
    [No Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes.
    Luo Q, Zhou L, Zhou N, Hu M.
    Front Public Health; 2022 Oct; 10():1016937. PubMed ID: 36330105
    [Abstract] [Full Text] [Related]

  • 38. Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis.
    Czech M, Rdzanek E, Pawęska J, Adamowicz-Sidor O, Niewada M, Jakubczyk M.
    BMC Endocr Disord; 2015 Oct 12; 15():57. PubMed ID: 26458540
    [Abstract] [Full Text] [Related]

  • 39. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.
    Liebl A, Prusty V, Valensi P, Kawamori R, Christiansen JS, Palmer AJ, Balschmidt P, Ligthelm R, Mohan V.
    Drugs; 2012 Jul 30; 72(11):1495-520. PubMed ID: 22818015
    [Abstract] [Full Text] [Related]

  • 40. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.
    Yang W, Gao Y, Liu G, Chen L, Fu Z, Zou D, Feng P, Zhao Z.
    Curr Med Res Opin; 2010 Jan 30; 26(1):101-7. PubMed ID: 19916705
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 3.